News

Moderately ill patients hospitalized with COVID-19 were less likely to require life support after receiving full-dose anticoagulation treatment, according to interim results of a multiplatform randomized trial.

University of Wisconsin, Madison investigators screened 145 student-athletes who were recovering from asymptomatic or mild-to-moderate coronavirus cases.

After setbacks to its own vaccine candidate, the major drug developer has agreed to aide in production for Europe-bound doses.

Unlike the influenza A virus H1N1 2009 pandemic, pregnancy was not identified as a high-risk condition for SARS-CoV-2.

The findings may have important implications on vaccine research and development.

Using the Defense Production Act to aid in the effort remains on the table.

Independent investigators assessed in vitro neutralization potency using the antibody therapy, Regen-Cov, against the B.1.1.7 and B.1.351 strains.

Roughly half the US population is now eligible to get a COVID-19 vaccine, according to health guidelines, but supply cannot keep up with demand.

Cheap, safe, and readily accessible preventative measures that modulate severe disease outcomes are desperately needed.

Preclinical evidence and observations have yielded mixed conclusions, but a new clinical study finds no negative effect to medication continuation.

On November 5, England went into a large scale lockdown to help curb the spread of the virus. This resurgence wasn’t unique to the UK though, but many have questioned the efficacy of such lockdowns, especially second ones.

New systematic review data suggest most patients who test positive without symptoms will remain asymptomatic over time.

A France-based assessment of the IL-1 inhibitor was ended early on the recommendation of the safety monitoring board early this year.

Findings may also provide profound protection for asthma by reducing severity of asthma attacks.

Company announced it will continue developing 2 investigational therapeutics.

The United States and China make up nearly half of the globes vaccinations.

However, there is a six-fold reduction in neutralizing titers in the B.1.351 variant from South Africa, so the company is exploring strategies aimed against new variants.

Saliva testing for coronavirus disease 2019 (COVID-19) is as effective as the standard nasopharyngeal tests, according to a new study by investigators at McGill University.

With the news that the Pfizer and BioNtech COVID-19 vaccine vials can provide an extra dose, the federal agency updated the labeling so as to enable usage of low dead-volume syringes to extract it.

Among people living with HIV, lower white blood cell counts were associated with smaller brain volume in the hippocampus and thalamus, a new study found, suggesting the possibility of generalizable neurologic signatures of HIV infections.

Good compliance to guidelines can help workplace and schools to reopen safely.

Intestinal-type metaplasia of the esophagus and stomach aberrantly express the proteins critical for SARS-CoV-2 binding.

In a move being ill-received by clinicians, the COVID-19 vaccine producer is lessening the count of vials being supplied to the government through July.

The method allows mitochondrial DNA levels to be quantified directly in the blood, without requiring intermediate steps.

Project aims for additional good-paying jobs, combatting the climate crisis, advancing racial equity, and building back better than before.

Presence of GI symptoms with COVID-19 was associated with increased likelihood of severe illness.

If the current recommended dosing schedules for the vaccines are not “feasible,” then the agency said vaccines may be scheduled for administration up to 42 days between the first and second doses.

The President declared a “full-scale wartime effort” to combat the ongoing pandemic.

The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.

Viral loads in treatment group were consistent with previously disclosed data from the BLAZE-1 trial.